GemVax & KAEL Co Ltd
KOSDAQ:082270
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GemVax & KAEL Co Ltd
KOSDAQ:082270
|
KR |
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IST:DGATE.E
|
TR |
|
Schindler Holding AG
SIX:SCHN
|
CH |
|
Humacyte Inc
NASDAQ:HUMA
|
US |
Intrinsic Value
Is GemVax & KAEL Co Ltd undervalued or overvalued?
See the intrinsic value estimate for GemVax & KAEL Co Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
GemVax & KAEL Co Ltd looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with GemVax & KAEL Co Ltd’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What GemVax & KAEL Does
GemVax & KAEL is a South Korean biopharmaceutical company that develops experimental medicines, with a focus on peptide-based drugs such as GV1001. Its work centers on treatments for diseases with limited options, including cancer and neurodegenerative conditions, and it also has roots in making plasma-derived and other specialty pharmaceutical products.
- Headquarters
- Korea KR
- Employees
- 182
- IPO date
- Jun 24, 2005
Revenue & Expenses Breakdown
GemVax & KAEL Co Ltd
Earnings Waterfall
GemVax & KAEL Co Ltd
The intrinsic value for GemVax & KAEL Co Ltd (082270) under the Base Case is hidden KRW.
Compared with the current market price of 9 260 KRW, the stock appears hidden.